June 27th, 2023

Meta Platforms, Inc. (Nasdaq: META), a prominent social media and technology company, was maintained with a Buy rating by Citigroup, who raised the price target from $315 to $360.  Despite $META closing at $287.05 on Tuesday, the revised pric. Read more

June 27th, 2023

AeroVironment, Inc. (Nasdaq: AVAV) reported fourth-quarter fiscal 2023 adjusted EPS of $0.99, slightly below the consensus estimate of $1.01. Looking ahead to the full-year fiscal 2024, the company anticipates revenue ranging between $630 million . Read more

June 27th, 2023

The U.S. Department of State, the U.S. Department of the Treasury, the U.S. Department of Commerce, the U.S. Department of Homeland Security, the U.S. Department of Labor, and the United States Agency for International Development issued a business r. Read more

June 27th, 2023

Shares of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) tumbled more than 8% during intraday trading in response to the company receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). The CRL was issued for th. Read more

June 27th, 2023

Shares of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) soared over 100% in pre-market trading following the release of initial clinical data for BDTX-1535. The investigational drug, a fourth-generation epidermal growth factor receptor (EGFR) Maste. Read more

June 27th, 2023

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) posted third-quarter fiscal 2023 adjusted earnings per share (EPS) of $1.00, falling short of the consensus estimate of $1.07. For the full fiscal year 2023, the company revised its adjusted EPS guidanc. Read more

June 27th, 2023

Shares of American Equity Investment Life Holding Company (NYSE: AEL) experienced a significant surge in premarket trading, rising over 10%. The boost came after the company confirmed receiving a takeover proposal from Brookfield Reinsurance Ltd. (NY. Read more

June 27th, 2023

Applied Digital Corporation (Nasdaq: APLD) has revealed in a regulatory filing with the SEC a revenue guidance that falls below analysts' estimates. For the fiscal fourth quarter of 2023, the company expects that its overall revenues will be appro. Read more

June 26th, 2023

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company specializing in ophthalmic therapeutics, has been maintained at a Buy rating by HC Wainwright & Co., who raised the price target from $40 to $44.  $TARS closed at $17.15. Read more

June 26th, 2023

Shares of Biomea Fusion, Inc. (Nasdaq: BMEA) surged to $32.87 during early trading on Monday, driven by positive clinical data from its Phase II study on BMF-219 in type 2 diabetes patients. However, by the end of the trading session, $BMEA closed at. Read more